EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, MyelomaSeptember 22, 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, MyelomaSeptember 18, 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, MyelomaAugust 22, 2023
FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, MyelomaAugust 14, 2023
Watch the recording of the EHA 2023 highlights webinarAL amyloidosis, MPE, Myeloma, VideosJuly 10, 2023
Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern EuropeAccess, MyelomaJune 25, 2023
Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights AL amyloidosis, Conferences, MPE, MyelomaJune 14, 2023
